Fair Value Calculator Fair Value Calculator
EN DE

003000 (003000) Fair Value & Analysis

Healthcare · Market cap 442B KRW

0 003000 003000 · KO
Price4,035 KRW
Fair Value2,730 KRW
Upside-32.3%
Quality45/100
Watch 003000 for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range 1,761 KRW – 3,500 KRW

Fair value as of: Jun 25, 2026

From 23 valuation models · updated 7 days ago

Share price −11.8% over the past month.

Price vs Fair Value (12 months)

8,796 KRW 2,940 KRW Fair Value 2,730 KRW Jun 2025 Jun 2026

12‑month range 2,940 KRW – 8,796 KRW · fair‑value band 1,761 KRW – 3,500 KRW · the 4,035 KRW price screens above the 2,730 KRW fair value. As of Jun 25, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

003000 (003000) currently trades at 4,035 KRW, while our model-based Fair Value estimate is 2,730 KRW — implying the stock looks roughly 32.3% overvalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 003000 generated revenue of 201B KRW at a net margin of 6.9%. Revenue declined 0.1% year over year. It earns a return on equity of 4.8%. Fundamentals as of Jun 25, 2026

Key figures & financial health

Revenue (TTM) 201B KRW
Revenue growth (YoY) -0.1%
Net margin 6.9%
Return on equity 4.8%
Free cash flow 10.3B KRW FY2025
Operating margin 2.3%
More key figures
Dividend yield 2.8%
EPS growth (YoY) +64.3%

Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

003000 reported revenue of 201B KRW in FY2025 versus 182B KRW in FY2021, a compound +2.4%/yr. Reported net income was 12.6B KRW in FY2025.

Revenue +2.4%/yr
FY21 182B KRW
FY22 191B KRW
FY23 126B KRW
FY24 160B KRW
FY25 201B KRW
Net income
FY21 −917M KRW
FY22 −2.5B KRW
FY23 −31.3B KRW
FY24 −2.6B KRW
FY25 12.6B KRW

Is 003000 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).

Stock Price Fair Value vs Fair Value
1276 1276 HK$57.85 HK$29.84 -48%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.01 ¥26.59 -43%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,782 ₹915.92 -49%
Zoetis Inc Z1TS34 R$26.19 R$26.01 -1%
Hansoh Pharmaceutical Group 3692 HK$29.58 HK$18.75 -37%
Divi's Laboratories Limited DIVISLAB ₹6,788 ₹2,035 -70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 003000 (003000) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 2,730 KRW versus a price of 4,035 KRW — about −32% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 003000?
Our model-based fair value for 003000 is 2,730 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 4,035 KRW.
What is the quality score of 003000?
003000 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 003000 (003000)?
003000 reported trailing-twelve-month revenue of about 201B KRW (latest available figure, as of Jun 25, 2026).
What is the net profit margin of 003000?
The net profit margin of 003000 is about 6.9%, meaning it keeps roughly 6.9% of revenue as net income. Based on the latest reported figures.
Does 003000 pay a dividend?
003000 currently shows a dividend yield of about 2.79% relative to its recent price (as of Jun 25, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.